BRUSSELS (Reuters) - Belgian pharmaceuticals group UCB said on Monday that sales of its three new main products had for the first time overtaken those of its expiring blockbuster epilepsy treatment Keppra and retained its full-year guidance.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment